Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Zenas Biopharma
ZBIO.US
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc.
1.931 T
ZBIO.USMarket value -Rank by Market Cap -/-

Financial Score

02/02/2026 Update
D
BiotechnologyIndustry
Industry Ranking218/395
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-68.33%E
    • Profit Margin-1265.99%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY0.00%C
    • Net Profit YoY-47.24%D
    • Total Assets YoY-20.18%E
    • Net Assets YoY-45.35%E
  • Cash ScoreD
    • Cash Flow Margin-7.90%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0.04E
  • Debt ScoreB
    • Gearing Ratio39.00%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    U.S. stock market movement report: Alumis surges 150%, Mobix Labs plummets 46%, tech stocks trading actively

    Overview of the US Stock Market In the past hour, the US stock market has shown significant sector rotation, with technology and pharmaceutical sectors performing particularly well. Capital flows have clearly favored small-cap stocks and thematic stocks, especially those companies with major news or technological breakthroughs recently. Market sentiment is active, with considerable volatility, and short-term enthusiasm continues to rise. The stock with the largest movement, Alumis, leads the market with a 150.64% increase, and trading volume has significantly expanded, indicating strong investor confidence in its future development. The strong performance of this stock may be related to its innovative breakthroughs in the pharmaceutical field, attracting substantial capital attention. Strong stocks: 1. Autozi Internet Tech Global: up 51.24%, with increased trading volume, driven by the enthusiasm in the technology sector pushing its stock price significantly higher. 2. PMGC: up 31.37%, with noticeable capital inflow, and the market is optimistic about its future growth expectations. 3. Brand Engagement Network: up 29.94%, with active short-term capital and high market sentiment. 4. WAVE Life Sciences: up 27.40%, driven by the strong performance of the pharmaceutical sector pushing its stock price upward. 5. Sky Quarry: up 26.15%, with increased attention on environmental themes driving the stock price up. 6. Banzai: up 22.29%, with increased market recognition of its business model and noticeable capital inflow

    Tracking Unusual Activity·
    Tracking Unusual Activity·